ZOM should I hold?

Advice: Hold your Zomedica (ZOM) shares, but closely monitor the company's performance and market conditions for potential reassessment.

Analysis:

1. Financial Performance: Zomedica's P/E ratio of -8.46 suggests negative earnings, which is confirmed by the negative EPS figures. The company is yet to achieve profitability, but the recent stabilization in EPS (from -$0.01 to $0) indicates potential improvement.

2. Revenue Growth: The lack of year-on-year revenue growth data may raise concerns about the company's top-line growth potential, which is crucial for long-term sustainability.

3. Profit Margins: Improving net profit margins from -444.78% to -67.92% show operational efficiency improvements, but the company still faces challenges in generating profits.

4. Debt Management: The absence of debt in the company's capital structure indicates a sound financial position, which supports stability and flexibility in operations.

5. Market Performance: The recent 5.26% increase in ZOM's stock price to $0.14 reflects positive market sentiment, which might be driven by factors not captured in the financial data.

Conclusion: Given Zomedica's negative earnings and uncertainties around revenue growth, holding your shares could be justified by the potential for future profitability. However, the negative EPS and the company's current financial challenges warrant close monitoring. Stay informed about Zomedica's product development, market uptake, and overall performance to make timely decisions based on future updates.